Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiovascular risk assessment and triptans.

Vasilios Papademetriou1

  • 1Hypertension Research Center, Georgetown University, Wasington, DC 20422, USA.

Headache
|May 20, 2004
PubMed
Summary

Triptan prescribing requires careful cardiovascular risk assessment. Patients with low risk can take triptans, while those with established heart disease or intermediate risk need further evaluation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term effects of renal denervation on hypertension management: insights from an ESH center of excellence and a meta-analysis of current evidence.

Journal of hypertension·2025
Same author

Comparison of three creatinine-based equations to predict adverse outcome in a cardiovascular high-risk cohort: an investigation using the SPRINT research materials.

Clinical kidney journal·2024
Same author

Right ventricular performance in patients with heart failure with mildly reduced ejection fraction: the forgotten ventricle.

The international journal of cardiovascular imaging·2022
Same author

Hypertensive urgencies during the first wave of the COVID-19 pandemic in a tertiary hospital setting: a U-shaped alarming curve.

Archives of medical science : AMS·2022
Same author

Blood Pressure Intervention and Control in SPRINT.

Hypertension (Dallas, Tex. : 1979)·2022
Same author

Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium.

Circulation·2022

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Triptans are effective migraine treatments but carry cardiovascular risks.
  • Assessing cardiovascular risk in patients without diagnosed disease is challenging.
  • A structured framework for risk assessment is needed for safe triptan prescription.

Purpose of the Study:

  • To discuss coronary heart disease pathophysiology and cardiovascular risk assessment.
  • To provide a framework for evaluating patients for triptan therapy.
  • To guide decisions on prescribing triptans based on cardiovascular risk.

Main Methods:

  • Review of coronary heart disease pathophysiology.
  • Application of current cardiovascular risk assessment guidelines.
  • Stratification of patients into low, intermediate, and high cardiovascular risk categories.

Main Results:

  • Low-risk patients (0-1 risk factor) may receive triptans without intensive evaluation.
  • High-risk patients (established cardiovascular disease) should not receive triptans.
  • Intermediate-risk patients (≥2 risk factors) require cardiovascular evaluation before triptan use.

Conclusions:

  • Cardiovascular risk assessment is crucial for safe triptan prescribing.
  • Existing risk models have limitations in predicting acute coronary events.
  • Guidelines should be applied considering the inability to accurately quantify plaque burden.

Related Experiment Videos